Insomnia in the Geriatric Population

3/1/2023 Family Medicine — Ed Day Amanda d'Almeida, PGY-1

Background

- Insomnia is a common problem in primary care, more than 5.5 million outpatient visits annually (10)
- Associated with older age; female sex; mental illness; poor general health; lower socioeconomic status (1, 2)
- Sleep problems in the elderly are often undiagnosed and undertreated
- Inadequate sleep is associated with decreased memory ,increased risk of falls, and impaired functional performance.
- Medications have worrisome side effects in the elderly population

Outline

Overview

Normal Sleep in the Aging Population

Total Sleep Time (TST): Decreases with age

Sleep efficiency: Decreases with age

 Ratio between the time a person spends asleep and the total time dedicated to sleep

Sleep maintenance: Wakefulness after sleep onset (WASO) increases with age

Elderly patient population should be getting 7-9 hours of sleep Sleep duration recommendations by age from the National Sleep Foundation*



* These recommendations are very similar, but not identical to those from the American Academy of Sleep Medicine (AASM).^[1,2]

Paruthiet al. (2016)

Sleep architecture

Rapid Eye Movement (REM) (5)

Non Rapid Eye Movement (NREM)

-Stage 1 and 2: light sleep

-Stage 3 and 4: deep sleep

Aging and changes in sleep architecture

- NREM Deep Sleep (Stage 3 and 4) decreases with age
- NREM stage 1 and stage 2 increases with age
- REM sleep decreases with age (but associations are weak) (3)



Li et al. (2017)

Comparison of young adults versus Elderly sleep architecture



Sleep changes in the elderly compared with the young adult. Reproduced with permission from the 1999 issue of *American Family Physician*. Copyright © 1999 American Academy of Family Physicians. (5)

Definition of Insomnia

DSM- 5, these must be present for at least 3 months and must occur at least 3 nights per week.

1)Difficulty initiating sleep

2)Difficulty maintaining sleep

3)Early-morning awakening with inability to return to sleep (7)

Short-term insomnia and chronic insomnia (6)

Significance of Insomnia

- Increased risk for diabetes and metabolic syndrome
 (7)
- Associated with significant morbidity and higher rates of depression and suicidality in geriatric population (7)
- Incidence of HTN was 3.8x higher (8)
- Incidence of heart failure 4.5x higher (9)
- Brain health: Sleep duration correlated with amyloid plaques (11)
- Sleep disturbance is associated with a > 50% increased risk for Alzheimer's disease.(12)

Approach to Chronic Insomnia in Elderly: Evaluation

History

- including substance use and psychiatric history
- ask about sleep initiation, sleep maintenance and early awakenings
- Review of medications and supplements

Assessment using a validated sleep quality rating scale

PHQ-2 and GAD-7

Validated screening tools for chronic insomnia

• Pittsburgh Sleep Quality Index:

- PSQI > 5 has sensitivity (89%) and specific (86.5%) for differentiating "poor" from "good" sleepers-Time to complete: 5–10 minutes
- Insomnia Severity Index: Validated for ages 17-84
- Insomnia Symptoms Questionnaire
- Epsworth Sleepiness Scale (ESS): ~5 min to complete
- Sleep problems questionnaire (17)

The Pittsburgh Sleep Quality Index (PSQI)

2

Instructions: The following questions relate to your usual sleep habits during the past month only. Your answers should indicate the most accurate reply for the majority of days and nights in the past month. Please answer all questions. During the past month,

1. When have you usually gone to bed?

2. How long (in minutes) has it taken you to fall asleep each night?

3. When have you usually gotten up in the morning?

4. How many hours of actual sleep do you get at night? (This may be different than the number of hours you spend in bed)

 During the past month, how often have you had trouble sleeping because you 	Not during the past month (0)	Less than once a week (1)	Once or twice a week (2)	Three or more times week (3)
a. Cannot get to sleep within 30 minutes				
b. Wake up in the middle of the night or early morning				
c. Have to get up to use the bathroom				
d. Cannot breathe comfortably				
e. Cough or snore loudly				
f. Feel too cold				
g. Feel too hot				
h. Have bad dreams				
i. Have pain				
j. Other reason(s), please describe, including how often you have had trouble sleeping because of this reason(s):				
6. During the past month, how often have you taken medicine (prescribed or "over the counter") to help you sleep?				
During the past month, how often have you had trouble staying awake while driving, eating meals, or engaging in social activity?				
8. During the past month, how much of a problem has it been for you to keep up enthusiasm to get things done?				
	Very good (0)	Fairly good (1)	Fairly bad (2)	Very bad (3)
9. During the past month, how would you rate your sleep quality overall?				

Component 1	#9 Score
Component 2	#2 Score (<15min=0; 16-30 min=1; 31-60 min=2, >60 min=3) + #5a Score (if sum is equal 0=0; 1-2=1; 3-4=2; 5-6=3)
Component 3	#4 Score (>7=0; 6-7=1; 5-6=2; <5=3)C3
Component 4	(total # of hours asleep)/(total # of hours in bed) x 100 >85%=0, 75%-84%=1, 65%-74%=2, <65%=3
Component 5	Sum of Scores #5b to #5j (0=0; 1-9=1; 10-18=2; 19-27=3)
Component 6	#6 Score C6
Component 7	#7 Score + #8 Score (0=0; 1-2=1; 3-4=2; 5-6=3) C7

Add the seven component scores together _____ Clobal PSQI Score

Buysse, D.J., Reynolds III, C.F., Monk, T.H., Berman, S.R., & Kupfer, D.J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Journal of Psychiatric Research, 28(2), 193-213.

Reprinted with permission from copyright holder for educational purposes per the University of Pittsburgh, Sleep Medicine Institute, Pittsburgh Sleep Quality Index (PSQI) website at http://www.sleep.pitt.edu/content.asp?id=1484&subid=2316.

Identify the cause of chronic insomnia

1) Primary sleep disorders

Circadian rhythm disorders:

1) Advanced sleep-phase syndrome

2) Delayed sleep-phase syndrome

Sleep apnea (obstructive, central, or mixed), Restless leg syndrome, Periodic limb movement disorders (nocturnal myoclonus), REM, behavior disorder 2) Physical illness:

Pain: arthritis, musculoskeletal pain, other painful conditions

Cardiovascular: heart failure, nocturnal breathlessness, nocturnal angina

Pulmonary: chronic obstructive pulmonary disease, allergic rhinitis (nasal obstruction)

Gastrointestinal: gastroesophageal reflux disease, pepticulcer disease, constipation, diarrhea, pruritus ani

Urinary: nocturia and urinary retention, incomplete bladder emptying, incontinence

Central nervous system: stroke, Parkinson disease, Alzheimer disease, seizure disorder

Psychiatric illness: **anxiety, depression**, psychosis, dementia, delirium

Pruritus

Menopause (hot flushes)

3) Behavioral: daytime nap, early retirement to bed, use of bed for other activities (eg, reading and watching television), heavy meals, lack of exercise, and sedentary lifestyle

4) Environmental: noise, light and other disturbances, extreme temperatures, uncomfortable bedding, and lack of exposure to sunlight (2)

Identify the cause, continued

5) Medications: (2)

Central nervous system stimulants: sympathomimetics, caffeine, nicotine, antidepressant, amphetamines, ephedrine, phenylpropanolamine Phenytoin

Antidepressants	bupropion,	selective serotonin	reuptake inhibitors,	venlataxin
			· · · · ·	

Anti-Parkinsonian agents: levodopa

Decongestants: pseudoephedrine

Bronchodilators: theophylline

Cardiovascular: **B-blockers**, diuretics

Antihypertensives: clonidine, methyldopa, corticosteroids

Histamines, H2 blockers: cimetidine

Anticholinergics

Alcohol

Herbal remedies

Stimulant laxative

Management

- Physical examination, appropriate lab test
- Consider 2-week sleep diary

Treatment

- Effective treatment of the primary problem
- Sleep hygiene measures
- Nonpharmacologic measures
- Pharmacologic intervention

Nonpharmacological interventions

Sleep Hygiene (may not be enough to cure insomnia, but a great first step Exercise:

• Moderate exercise in older patients improved sleep time, sleep onset latency, global sleep quality (15)

CBTI: First-line treatment

Cognitive behavioral therapy for insomnia (CBTI)

- First line treatment
- About 4-8 sessions
- Behavioral and Cognitive components
- Different modalities:
 - individual, in-person, televisits, ect.



CBT-I

- Short-term trials: CBT-I alone = CBT-I + medication , > Medication alone
- Longer-term trials (12-24 months) CBT-I alone or CBT-I + medication > Medication alone (16)
- CBT-I has greater efficacy than sleep hygiene education, especially for patients with comorbid conditions (2)
- American Academy of Sleep Medicine, the British Association for Psychopharmacology, the American College of Physicians, and the European Sleep Research Society all endorsed CBT-I or other behavioral therapies over medication as initial therapy (16)

Resources for CBT-I

• Resources: Under psychiatry at UCLA there is a UCLA insomnia clinic https://www.uclahealth.org/medicalservices/psychiatry/adult/ucla-insomnia-clinic/our-treatments

How Sleepio works

Online: Somryst, <u>Sleepio</u>, <u>VA Sleep Coach</u> app



Set your goals

to improve







Test your sleep You tell us what you want You complete an

in-depth questionnaire

Build your program We build your program based on your goals

Weekly lessons You meet your virtual sleep expert, The Prof

Pharmacologic intervention

 Not recommended for chronic use. Avoid use in older adults. (16)



Medications for primary insomnia treatment (2)

Medication class/name	Dose	Sleep Outcome	SOR	Adverse effects
Nonbenzodiazepines				
Eszopiclone	2 mg or 3 mg	Sleep-onset latency, sleep maintenance	В	Dizziness, dry mouth, headache, dementia, serious injury, falls with fracture, somnolence
Zaleplon	5 mg or 10 mg	Sleep-onset latency	В	Headache, dementia, somnolence, falls with fracture
Zolpidem 10 mg		Sleep-onset latency, sleep maintenance	В	Dizziness, sedation, headache, rebound insomnia after discontinuation, excessive sleepiness at dosese>10 mg, dementia, falls with fractures
Melatonin agonist				
Ramelteon	8 mg	Sleep-onset latency	В	Headache, nausea
Orexin-receptor antagonist				
Suvorexant	10 mg, 15/20 mg, or 20 mg	Sleep maintenance	В	Mild day time sedation
ТСА				
Doxepin	3 mg or 6 mg	Sleep maintenance	В	Somnolence, headaches

 ${\sf SOR}: {\sf strength} \ {\sf of} \ {\sf recommendation}$

Medications NOT recommended for primary insomnia treatment (2)

- Antidepressants: Mirtazapine, Trazodone
- Anticonvulsants: Tiagabine
- Antihistamine: Hydroxyzine, diphenhydramine
- Amino acid- L tryptophan
- Herbal supplement : Valerian root
- TCA: Amitriptyline
- Atypical antipsychotics: Olanzapine, quetiapine

American Academy of Sleep Medicine

- Physiological and Behavioral Treatment of Insomnia in Adults
- <u>We recommend that clinicians use multicomponent cognitive behavioral therapy for</u> insomnia for the treatment of chronic insomnia disorder in adults. (STRONG)
- We suggest that clinicians use multicomponent brief therapies for insomnia for the treatment of chronic insomnia disorder in adults. (CONDITIONAL)
- We suggest that clinicians use stimulus control as a single-component therapy for the treatment of chronic insomnia disorder in adults. (CONDITIONAL)
- We suggest that clinicians use sleep restriction therapy as a single-component therapy for the treatment of chronic insomnia disorder in adults. (CONDITIONAL)
- We suggest that clinicians use relaxation therapy as a single-component therapy for the treatment of chronic insomnia disorder in adults. (CONDITIONAL)
- We suggest that clinicians *not* use sleep hygiene as a single-component therapy for the treatment of chronic insomnia disorder in adults. (CONDITIONAL)(19)

American Academy of Sleep Medicine

- We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults. (WEAK)
- We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK)
- We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK)
- We suggest that clinicians use zolpidem as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK)
- We suggest that clinicians use triazolam as a treatment for sleep onset insomnia (versus no treatment) in adults. (WEAK)
- We suggest that clinicians use temazepam as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK) (20)

BEST PRACTICES IN SLEEP MEDICINE: RECOMMENDATIONS FROM THE CHOOSING WISELY CAMPAIGN

Recommendation	Sponsoring organization
Do not use benzodiazepines or other sedative- hypnotics in older adults as a first choice for insomnia, agitation, or delirium.	American Geriatrics Society
Avoid the use of hypnotics as primary therapy for chronic insomnia in adults; instead, offer cognitive behavior therapy and reserve medication for adjunctive treatment when necessary.	American Academy of Sleep Medicine
Do not routinely prescribe antipsychotic medications as a first-line intervention for insomnia in adults.	American Psychiatric Association
Source: For more information on the Choosing Wisely C	ampaign, see http://www.

choosing wisely campaign, see http://www. choosingwisely.org. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see http://www.aafp.org/afp/recommenda tions/search.htm.

Summary

Management:

Evaluation

- Thorough history
- Validated insomnia screening tool
 Treatment: Multifactorial
- CBTI!!!!
- Treat underlying medical/psychiatric conditions
- If medications are required, start with lowest dose and titrate upward slowly (FDA approved medications)
- Use sedating low-dose antidepressants for insomnia only when the older patient has comorbid depression
- Limit use of nonbenzodiazepine receptor agonist "Z-drugs"
- Avoid benzodiazepines, OTC medications, and offlabel medications
- When using pharmacologic treatment, always in conjunction with nonpharmacologic treatments

Sources

1)Salisbury-Afshar E. Management of Insomnia Disorder in Adults. Am Fam Physician. 2018 Sep 1;98(5):319-322. PMID: 30216028.

2) Kamel N, Gammack K. (2006). Insomnia in the Elderly: Cause, Approach, and Treatment. The American Journal of Medicine. 119(6): 463-469

3) Bhaskar S, Hemavathy D, Prasad S. Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J Family Med Prim Care. 2016 Oct-Dec;5(4):780-784. doi: 10.4103/2249-4863.201153. PMID: 28348990; PMCID: PMC5353813.

4) Li J, Vitiello MV, Gooneratne NS. Sleep in Normal Aging. Sleep Med Clin. 2018 Mar;13(1):1-11. doi: 10.1016/j.jsmc.2017.09.001. Epub 2017 Nov 21. PMID: 29412976; PMCID: PMC5841578.

5) Traupman, E. K., & Dixon, M. A. (2022). Cognitive-behavioral therapy for insomnia for primary care: Review of components and application for residents in primary care. *The International Journal of Psychiatry in Medicine*, 57(5), 423–433. <u>https://doi.org/10.1177/00912174221112466</u>

6) https://www.amjmed.com/article/S0002-93430501056-9/fulltext#tbl1

7) Smith et al. (2023). Insonia diagnosis and treatment across the lifespan. *The Journal of Family Practice.* 72, 18-28 8) Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, Bixler EO. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension. 2012 Oct;60(4):929-35. doi: 10.1161/HYPERTENSIONAHA.112.193268. Epub 2012 Aug 14. PMID: 22892811; PMCID: PMC3679545.

Sources continued

9) Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: a population study. Éur Heart J. 2014 Jun 1;35(21):1382-93. doi: 10.1093/eur/heartj/ehto19. Epub 2013 Mar 5. PMID: 23462728.

10) Traupman, E. K., & Dixon, M. A. (2022). Cognitive-behavioral therapy for insomnia for primary care: Review of components and application for residents in primary care. *The International Journal of Psychiatry in Medicine*, 57(5), 423-433. https://doi.org/10.1177/00912174221112466

11) Spira, JAMA Neurol 2013; 70: 1537-1543. 12) Bonnet, M., & Arand, D. (2022, April 15). Risk factors, comorbidities, and consequences of insomnia in adults. In R. Benca (Ed.). UpToDate., Retrieved January 30, 2023, from <u>https://www.uptodate.com/contents/risk-factors-comorbidities-and-consequences-of-insomnia-in-adults</u>

13) Ju, Y. S., Ooms, S. J., Sutphen, C., Macauley, S. L., Zangrilli, M. A., Jerome, G., Fagan, A. M., Mignot, E., Zempel, J. M., Claassen, J., & Holtzman, D. M. (2017). Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain: A Journal of Neurology, 140(8), 2104–2111.

15) Reid KJ, Baron KG, Lu B, Naylor E, Wolfe L, Zee PC. Aerobic exercise improves self-reported sleep and quality of life in older adults with insomnia. Sleep Med. 2010 Oct;11(9):934-40. doi: 10.1016/j.sleep.2010.04.014. Epub 2010 Sep 1. PMID: 20813580; PMCID: PMC2992829.

16) https://www.uptodate.com/contents/overview-of-the-treatment-of-insomnia-inadults?search=insomnia&source=search result&selectedTitle=1~150&usage type=default&display rank=1

17) (Mitchell, Bisdounis, L., Ballesio, A., Omlin, X., & Kyle, S. D. (2019). The impact of cognitive behavioural therapy for insomnia on objective sleep parameters: A meta-analysis and systematic review. Sleep Medicine Reviews, 47, 90–102. https://doi.org/10.1016/i.smrv.2019.06.002)

19) Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice quideline. J Clin Sleep Med. 2021;17(2):255–262.

20) Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349.

21) Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended amount of sleep for pediatric populations: A statement of the American Academy of Sleep Medicine. J Clin Sleep Med 2016; 12:785.

23) Matheson E, Hainer BL. Insomnia: Pharmacologic Therapy. Am Fam Physician. 2017 Jul 1;96(1):29-35. PMID: 28671376.

